Tirzepatide TFA (LY3298176 TFA) 是葡萄糖依赖性胰岛素营养多肽(GIP)和胰高血糖素样肽-1(GLP-1)受体双重激动剂,有潜力用于 2 型糖尿病的研究。
| 生物活性 | Tirzepatide TFA (LY3298176 TFA) is a dualglucose-dependent insulinotropic polypeptide (GIP)andglucagon-like peptide-1 (GLP-1) receptoragonist that is being developed for the treatment of type 2 diabetes[1]. |
| IC50& Target | Glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor[1] |
| Clinical Trial | |
| 分子量 | |
| Formula | |
| Sequence Shortening | Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |